| Existing Vaccines |
Dosage |
Advantages |
Drawback |
| Menveo® (MCV4) (Meningococcal polysaccharide (Serogroups A, C, Y and W-135) Diphtheria CRM197 Conjugate Vaccine) - Novartis |
0.5 ml - dose use for people between 2-55 years old a second dose after 2 months. (Intramuscular) |
Prevents against serogroups A, C, Y and W-135. |
Does not prevent N. meningitidis serogroup B infections. [27,28] |
| Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Aventis Pasteur |
0.5 ml - 2 doses schedule for children between 9 to 23 months, 3 months apart. 11-12; 1 dose. (Intramuscular) |
Prevents against serogroups A, C, Y and W-135. Can be used in infants. |
Does not prevent N. meningitidis serogroup B infections [29]. |
| Menomune®– A/C/Y/W-135 - Aventis Pasteur |
0.5ml - 1 dose, 2 years of age and older. (Intramuscular) |
Prevents against serogroups A, C, Y and W-135. |
Does not prevent N. meningitidis serogroup B infections [30]. |
